biote BTMD 深 滬
等待開盤 08-21 09:30:00 美东时间
1.49
+0.130
+9.56%
華盛通- 最 高1.68
- 今 開1.36
- 成交量 198.59万股
- 最 低 1.36
- 昨 收 1.36
- 總市值 5353.19万
- 52周最高 3.62
- 市盈率 靜 2.02
- 換手率 5.53%
- 52周最低 1.27
- 委 比 42.34%
- 總股本 3592.75万
- 歷史最高 12.08
- 量 比 18.12
- 振 幅 23.53%
- 歷史最低 1.27
- 每 手 1
- 風險率 0.52%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Capricor slips after report on potential Deramiocel rejection
Capricor Therapeutics (CAPR) was a notable decliner in biotech on Thursday after a report from STAT News renewed concerns about a potential rejection of the company’s lead candidate, Deramiocel, in th...
08-20 22:55
Vivoryon Therapeutics N.V. to Hold its 2026 Annual General Meeting on September 29, 2026
Vivoryon Therapeutics N.V. announced its 2026 Annual General Meeting will be held on September 29, 2026, at 11:00 a.m. CEST in Amsterdam. The company, focused on developing small molecule medicines for inflammatory and fibrotic kidney diseases, invites shareholders to attend. The agenda and documents are available on its website. Vivoryon's lead program, varoglutamstat, targets diabetic kidney disease. For more information, contact Dr. Manuela Ba...
08-18 16:30
Board-Certified Vascular and Endovascular Surgeon Performs First Commercial Symvess® Implantation; Cites Bioengineered Blood Vessel as “Revolutionary Advancement”
Humacyte's Symvess, the first FDA-approved bioengineered human blood vessel, is now being used in Arizona by Dr. Jeromy Brink, a vascular surgeon at Banner University Medical Center in Phoenix. Symvess is an off-the-shelf solution for urgent revascularization in adults with extremity arterial injury, eliminating the need to harvest veins from patients. Dr. Brink, who has performed four implants since gaining access two weeks ago, calls Symvess th...
08-18 12:00
美股大行评级 | Take-Two、Csquare、Standard获多家大行首予买入评级！潜在涨幅215.32%！HC Wainwright.升Innate Pharma(IPHA)目标价至7美元
今日重点评级关注：HC Wainwright & Co.：维持Innate Pharma"买入"评级，目标价从5美元升至7美元；HC Wainwright & Co.：维持Immix Biopharma"买入"评级，目标价从20美元升至25美元
08-11 11:45
美股大行评级 | 花旗下调美光科技目标价从1400美元降至1150美元；爱彼迎、Datadog、Cloudflare、Etsy、Natera、拉夫劳伦获多家大行上调目标价
今日重点评级关注：康托·菲茨杰拉德：维持InflaRx"超配"评级，目标价从4美元升至6美元；RBC Capital：维持Nuvation Bio"跑赢大市"评级，目标价从19美元升至20美元
08-10 19:24
TD Cowen Maintains Buy on Biote, Lowers Price Target to $2
TD Cowen analyst Jonna Kim maintains Biote (NASDAQ:BTMD) with a Buy and lowers the price target from $2.5 to $2.
08-08 05:16
Biote Q2 EPS $(0.23) Misses $0.04 Estimate, Sales $44.232M Miss $46.148M Estimate
Biote (NASDAQ:BTMD) reported quarterly losses of $(0.23) per share which missed the analyst consensus estimate of $0.04 by 675 percent. This is a 330 percent decrease over earnings of $0.10 per share from the same period last year. The company reported quarterly sales of $44.232 million which missed...
08-06 04:08
Biote Reaffirms FY26 Guidance For Revenue Above $190M And Adjusted EBITDA Above $38M
Biote reaffirmed its full year 2026 guidance for revenue above $190 million, Adjusted EBITDA above $38 million, and a return to procedure revenue growth in the second half of this year.
05-28 21:12
Biote Appoints CFO And Chief Business Officer Bob Peterson As Interim CEO And Director, Effective June 8; Bret Christensen Steps Down As CEO
Biote (NASDAQ:BTMD), a leader in innovative hormone optimization and healthy aging solutions that advance the healthspan of our practitioners' patients, today announced that Bob Peterson, Chief Financial Officer and
05-28 21:11
ImmunityBio acquiring U.S. rights to Tokyo strain of BCG
ImmunityBio (IBRX) on Saturday announced a licensing deal to acquire exclusive U.S. rights to a bladder cancer therapy called Bacillus Calmette-Guerin (BCG) treatment from Japan BCG Laboratory, a Japa...
05-17 02:11
